Compare REX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REX | NUVB |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1994 | N/A |
| Metric | REX | NUVB |
|---|---|---|
| Price | $43.94 | $4.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 159.3K | ★ 4.3M |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $650,487,000.00 | N/A |
| Revenue This Year | $19.45 | $203.82 |
| Revenue Next Year | N/A | $58.18 |
| P/E Ratio | $76.79 | ★ N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $30.02 | $1.57 |
| 52 Week High | $64.95 | $9.75 |
| Indicator | REX | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 37.58 | 53.69 |
| Support Level | $31.24 | $4.07 |
| Resistance Level | $49.85 | $5.16 |
| Average True Range (ATR) | 2.21 | 0.37 |
| MACD | -0.63 | 0.00 |
| Stochastic Oscillator | 15.22 | 39.52 |
REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.